Ozempic is a brand-name injectable medication containing the active ingredient semaglutide. It belongs to a drug class called GLP-1 receptor agonists, sometimes referred to as incretin mimetics. The FDA has approved Ozempic specifically for adults with type 2 diabetes, not for weight loss, though it often causes significant weight loss as a secondary effect.
How GLP-1 Receptor Agonists Work
Your small intestine naturally produces a hormone called GLP-1. This hormone plays several roles after you eat: it signals your pancreas to release insulin, it prevents your liver from dumping extra sugar into your bloodstream, and it tells your brain you’re full. The problem in type 2 diabetes is that this system doesn’t work well enough on its own.
Semaglutide is a manufactured version of GLP-1 that binds to the same receptors as the natural hormone but lasts much longer in the body. When you inject Ozempic, it triggers insulin release, blocks a sugar-raising hormone called glucagon, and slows how quickly your stomach empties food. That slower digestion means glucose enters your bloodstream more gradually, and you feel full longer after meals. These combined effects are what make it effective for blood sugar control and why people on it tend to lose weight.
What Ozempic Is Approved to Treat
Ozempic carries three FDA-approved uses, all in adults with type 2 diabetes:
- Blood sugar management, alongside diet and exercise
- Cardiovascular protection, to reduce the risk of heart attack, stroke, or cardiovascular death in people who also have established heart disease
- Kidney protection, to slow kidney decline in people who also have chronic kidney disease
Despite its reputation as a “weight loss drug,” Ozempic is not FDA-approved for weight loss. A separate product called Wegovy contains the same active ingredient, semaglutide, but at a higher dose and with an explicit approval for weight management. When doctors prescribe Ozempic specifically for weight loss, that use is considered off-label.
How It Performs in Clinical Use
In clinical trials, the 1.0 mg weekly dose of Ozempic lowered A1c (a measure of average blood sugar over roughly three months) by 1.5% to 1.8% after 30 to 56 weeks. For context, a reduction of 1% in A1c is generally considered clinically meaningful.
Weight loss is substantial even at the diabetes-focused doses. GLP-1 medications in this class can lead to roughly 15 to 20 percent body weight loss on average, significantly more than older diabetes medications. The SELECT trial, a large cardiovascular outcomes study, found that semaglutide produced a 20% reduction in major cardiovascular events (heart attacks, strokes, and cardiovascular death) in patients with obesity and established heart disease.
Dosing and How You Take It
Ozempic is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. You pick one day of the week and stick with it, at any time of day, with or without food. The medication comes in a prefilled pen.
Treatment starts at 0.25 mg per week for the first four weeks. This starting dose isn’t actually therapeutic; it’s designed to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg. From there, your doctor may increase it further based on your blood sugar response, up to a maximum of 2 mg per week. Each step up typically happens after at least four weeks at the current dose.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. In a two-year study of semaglutide, 82.2% of patients experienced some form of GI side effect, compared with 53.9% on placebo. The most common complaints are nausea, diarrhea, constipation, stomach pain, bloating, and vomiting. These effects are generally rated as mild to moderate rather than severe.
The good news is that they tend to fade. Because semaglutide slows stomach emptying, the gut needs time to adapt. Most GI side effects decrease noticeably after about 20 weeks of use. Starting at a low dose and increasing gradually is the main strategy for keeping these symptoms manageable during the adjustment period.
Safety Warnings and Contraindications
Ozempic carries a boxed warning, the FDA’s most serious label alert, related to thyroid tumors. In animal studies, semaglutide caused thyroid C-cell tumors at doses relevant to human use. Whether this risk translates to humans remains unknown, but as a precaution, Ozempic is strictly off-limits for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
The drug is also contraindicated for anyone who has had a serious allergic reaction to semaglutide or any of Ozempic’s inactive ingredients.
Ozempic vs. Wegovy vs. Rybelsus
All three medications contain semaglutide, but they serve different purposes and come in different forms. Ozempic is a once-weekly injection approved for type 2 diabetes. Wegovy is also a once-weekly injection but is approved for weight management in adults and children aged 12 and older, and it reaches a higher maximum dose. Rybelsus is a daily oral tablet of semaglutide approved for type 2 diabetes, not weight loss. It must be taken on an empty stomach with only a small sip of water.
The key distinction is regulatory, not chemical. Your body processes the same active molecule regardless of which product you use. But the approved doses, titration schedules, and covered indications differ, which affects what insurance will pay for and what your doctor can prescribe for a given condition.
Storing the Ozempic Pen
Before first use, keep your Ozempic pen in the refrigerator between 36°F and 46°F. Once you’ve used the pen for the first time, it stays good for 56 days. During that period, you can store it either at room temperature (59°F to 86°F) or back in the refrigerator. Do not freeze it, and keep it away from direct heat or sunlight.